CD274 and non-small cell lung carcinoma: Several other observational studies from the US, Europe, and Israel have been published recently that evaluated outcomes with first-line pembrolizumab or other ICI monotherapy for similar patient populations with advanced NSCLC, PD-L1 expression ≥50%, and no genomic alterations (23–27).